Feasibility and Acceptability of HCV Treatment in Pregnancy

RECRUITING

I'm interested ...!!

Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year. Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.

Conditions:

🦠 Hepatitis C 🦠 Pregnancy Complications

🗓️ Study Start (Actual) 1 February 2024

🗓️ Primary Completion (Estimated) 28 February 2026

✅ Study Completion (Estimated) 28 February 2026

👥 Enrollment (Estimated) 50

🔬 Study Type OBSERVATIONAL

📊 Phase N/A

Locations:

📍 Saint Louis, Missouri, United States

📋 Eligibility Criteria

Description

Inclusion Criteria:

* Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.

Exclusion Criteria:

Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)

Sexes Eligible for Study: FEMALE

Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 6 March 2024
First Submitted that Met QC Criteria 11 April 2024
First Posted 16 April 2024

Study Record Updates

Last Update Submitted that Met QC Criteria 11 April 2024
Last Update Posted 16 April 2024
Last Verified April 2024